Evidence map›Paper›PMID 39020106›Full record

ArticleNeuromolecular medicine2024

The CD44s Isoform is a Potential Biomarker for Predicting Craniopharyngioma Recurrence in Children.

K Bajdak-Rusinek, N Diak, E Gutmajster, A Fus-Kujawa, M Ciupińska, B Kalina-Faska, A Trybus, M Grajek, M Kalina, M Mandera

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuromolecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The EMT status in the primary tumor of adamantinomatous craniopharyngioma predict postoperative recurrence in children.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

K Bajdak-RusinekDepartment of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752, Katowice, Poland. kbajdak-rusinek@sum.edu.pl.
N DiakDepartment of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752, Katowice, Poland.
E GutmajsterBiotechnology Centre, Silesian University of Technology, Gliwice, Poland.
A Fus-KujawaDepartment of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752, Katowice, Poland.
M CiupińskaDepartment of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, 40-752, Katowice, Poland.
B Kalina-FaskaDepartment of Pediatrics and Pediatric Endocrinology, Faculty of Medical Science, Medical University of Silesia, Katowice, Poland.
A TrybusDepartment of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752, Katowice, Poland.
M GrajekCenter for Cardiovascular Research and Development, American Heart of Poland, 40-028, Katowice, Poland.
M KalinaDepartment of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752, Katowice, Poland.
M ManderaDepartment of Pediatric Neurosurgery, Medical University of Silesia, Katowice, Poland.

Funding

Institutional grant of Medical University of Silesia KNW-1-202/N/8/O
6 · The paper itself

Abstract

Adamantinomatous craniopharyngioma (ACP) is an intracranial tumor considered partly malignant due to its ability to infiltrate surrounding structures and tendency to relapse despite radical resection. CD44 is a known stem cell marker in ACP and is upregulated in cell clusters of invasive ACP protrusions; however, the functions of its alternative splicing isoform variants, CD44s and CD44v1-10, have not yet been studied in terms of ACP recurrence, despite their confirmed roles in cancer development and progression. In this study, we first confirmed the difference in total CD44 expression between samples from patients who experienced relapse and those from patients who did not. Moreover, our findings showed that, in recurrent samples, the predominant isoform expressed was CD44s, which might indicate its significance in predicting ACP recurrence. The association between increased CD44 expression and recurrence may lead to the development of prognostic markers of ACP aggressiveness and relapse potential; however, further studies are needed to clarify the exact mechanism of CD44 expression.

Indexed as

Alternative SplicingBiomarkers, TumorCraniopharyngiomaHyaluronan ReceptorsNeoplasm Recurrence, LocalPituitary NeoplasmsProtein IsoformsAdolescentChildChild, PreschoolFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsProtein IsoformsCD44ChildrenCraniopharyngiomaTumor recurrence

Identifiers

PMID39020106
PMCPMC11254967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.